Pharma Mar Stock Price, News & Analysis (OTCMKTS:PHMMF)

$2.07 0.00 (0.00 %)
(As of 02/25/2018 04:24 AM ET)
Previous Close$2.07
Today's Range$2.00 - $2.07
52-Week Range$1.84 - $4.80
Volume5,493 shs
Average Volume7,198 shs
Market Capitalization$460.88 million
P/E RatioN/A
Dividend YieldN/A
Beta-7.7

About Pharma Mar (OTCMKTS:PHMMF)

Pharma Mar logoPharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. It develops and commercializes YONDELIS, a novel, multimodal, synthetically produced antitumor agent for the treatment of advanced soft tissue sarcomas as a single-agent, as well as for relapsed ovarian cancer in combination with Doxil/Caelyx. The company also has three other clinical-stage programs, including PM1183, plitidepsin, and PM184, which are under development for various types of solid and hematological cancers. In addition, it engages in molecular diagnostics; researching therapeutic applications of gene silencing; and chemical business. The company was founded in 1986 and is based in Madrid, Spain.

Receive PHMMF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PHMMF
CUSIPN/A
Phone34-91-846-6000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$200.26 million
Price / Sales2.30
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares222,650,000

Pharma Mar (OTCMKTS:PHMMF) Frequently Asked Questions

What is Pharma Mar's stock symbol?

Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."

Who are some of Pharma Mar's key competitors?

How do I buy Pharma Mar stock?

Shares of Pharma Mar can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharma Mar's stock price today?

One share of Pharma Mar stock can currently be purchased for approximately $2.07.

How big of a company is Pharma Mar?

Pharma Mar has a market capitalization of $460.88 million and generates $200.26 million in revenue each year.

How can I contact Pharma Mar?

Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The company can be reached via phone at 34-91-846-6000.


MarketBeat Community Rating for Pharma Mar (PHMMF)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Pharma Mar and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pharma Mar (OTCMKTS:PHMMF) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Pharma Mar (OTCMKTS:PHMMF)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Pharma Mar (OTCMKTS:PHMMF) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.07 EPS
Next Year EPS Consensus Estimate: $-0.05 EPS

Dividends

Dividend History for Pharma Mar (OTCMKTS:PHMMF)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pharma Mar (OTCMKTS PHMMF)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Pharma Mar (OTCMKTS PHMMF) News Headlines

Source:
DateHeadline
PharmaMars Lurbinectedin ATLANTIS trial design and data in small-cell lung cancer will be an oral presentation at the IASCLC´s annual meetingPharmaMar's Lurbinectedin ATLANTIS trial design and data in small-cell lung cancer will be an oral presentation at the IASCLC´s annual meeting
finance.yahoo.com - February 20 at 4:54 PM
PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2PharmaMar Has Published the Results of Its Antibody Conjugate Active in Breast, Ovarian and Gastric Cancers that Express HER2
finance.yahoo.com - February 16 at 9:07 AM
PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug ConjugatesPharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates
finance.yahoo.com - February 14 at 9:11 AM
Pharma Mar (PHMMF) Rating Lowered to Sell at Zacks Investment ResearchPharma Mar (PHMMF) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 25 at 11:20 AM
PharmaMar has Requested the Process of Re-Examination for Aplidin® from the EMAPharmaMar has Requested the Process of Re-Examination for Aplidin® from the EMA
finance.yahoo.com - January 3 at 9:32 AM
PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) With Megapharm in IsraelPharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) With Megapharm in Israel
finance.yahoo.com - January 2 at 8:43 AM
Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma MultiplePlitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple
finance.yahoo.com - December 12 at 10:43 AM
PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH MeetingPharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting
finance.yahoo.com - December 11 at 9:18 AM
Pharma Mar (PHMMF) Presents At Stifel 2017 Healthcare Conference - SlideshowPharma Mar (PHMMF) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 10:56 AM
Phase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMCPhase III Trial With Zepsyre® in Small-Cell Lung Cancer (ATLANTIS) to Continue on the Basis of Positive Recommendation by IDMC
finance.yahoo.com - November 18 at 10:56 AM
PharmaMar to Present at the Stifel 2017 Healthcare ConferencePharmaMar to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 15 at 7:28 AM
PharmaMar Presents Positive Results from a Phase II Study of lurbinectedin in Ewings Sarcoma at the CTOS International CongressPharmaMar Presents Positive Results from a Phase II Study of lurbinectedin in Ewing's Sarcoma at the CTOS International Congress
finance.yahoo.com - November 14 at 6:46 AM
PharmaMar and Boryung Pharm Sign A Licensing Agreement for Zepsyre® (lurbinectedin) in KoreaPharmaMar and Boryung Pharm Sign A Licensing Agreement for Zepsyre® (lurbinectedin) in Korea
finance.yahoo.com - November 7 at 8:46 AM

SEC Filings

Pharma Mar (OTCMKTS:PHMMF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Pharma Mar (OTCMKTS PHMMF) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.